Majella B Lavin

Majella B. Lavin is an accomplished finance professional with extensive experience in process reengineering and transformation initiatives across the pharmaceuticals and healthcare sectors. Currently serving as Director, Global Process Owner C2C at Ball Corporation and Director of Transformation and Strategy at Optum, Majella has successfully managed large teams and portfolios, including overseeing a $22 billion accounts receivable portfolio at Optum. Prior roles include Director of Finance Processes at Alexion Pharmaceuticals, where leadership involved global responsibilities for Order to Cash and compliance reporting, and various positions at Pfizer focused on Order to Cash transformation and operational management. Educational credentials include studies at UCD Michael Smurfit Graduate Business School.